A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth
| City: |
|
Louisville |
| State: |
|
Kentucky |
| Zip Code: |
|
40207 |
| Conditions: |
|
Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial |
| Purpose: |
|
In the continuing efforts to understand the benefits and risks of in utero exposure to 17P
this study is designed to evaluate differences in developmental outcomes of children, aged
23 to 25 months, born to mothers who participated in the 17P Efficacy Trial sponsored by
Hologic (Protocol number 17P-ES-003).
|
| Study Summary: |
|
This will be a prospective, noninterventional follow-up study designed to provide a
developmental assessment of children born to mothers who participated in the 17P Efficacy
Trial. When subjects reach an age of 23 months after adjustment for gestational age, they
will be screened for developmental delay using the 24 month ASQ version 3. Subjects who
score positive (fall below the specified cut-off) for developmental delay in 1 or more
domains will be referred for the 24 month Bayley Scales of Infant and Toddler Development
(3rd edition, Bayley-III) and a neurological examination.
|
| Criteria: |
|
Inclusion Criteria:
- 1. Maternal enrollment which resulted in a live birth in the 17P Efficacy Trial: A
Multi-center, Randomized, Double-blind Study of Hydroxyprogesterone Caproate
Injection, 250 mg/mL, Versus Vehicle for the Prevention of Preterm Birth in Women
With a Previous Singleton Spontaneous Preterm Delivery.
2. During their involvement in the above protocol, mothers must have received at
least one dose of study drug (Safety population).
3. Children between 22 and 25 months of age adjusted for gestational age.
Exclusion Criteria:
- 1. There is no parent/legal guardian available to sign an informed consent. 2. Born
to women who are unblinded to study group assignment.
|
| NCT ID: |
|
NCT01146990 |
| Primary Contact: |
|
Study Director
Jim Joffrion
KV Pharmaceutical Company
Jim Joffrion
Phone: 314-645-6600
Email: jjoffrion@kvph.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Louisville, Kentucky 40207
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|